Cases & Deals

  • Home
  • Practices
  • NGM Biopharmaceuticals completes $107 million IPO

Share

NGM Biopharmaceuticals completes $107 million IPO

April 2019

Client(s) NGM Biopharmaceuticals, Inc.

Jones Day served as IP counsel in connection with the $107 million initial public offering of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM). NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.